Filtered By:
Source: International Journal of Cardiology
Drug: Aspirin
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 22 results found since Jan 2013.
Stroke risk and suboptimal thromboprophylaxis in Chinese patients with atrial fibrillation: Would the novel oral anticoagulants have an impact?
Abstract: Background: The risk of stroke associated with atrial fibrillation (AF) is higher in Far Eastern population than in Western population, and warfarin use suboptimal. There is uncertainty whether the novel oral anticoagulants (NOACs) would have a major impact on stroke prevention in Far Eastern populations with AF.Objectives: We investigated current antithrombotic therapy use on stroke and bleeding risk, determinants of warfarin use and performed a modeling analysis of the net clinical benefit of the NOACs (apixaban, dabigatran) in a large cohort of Chinese patients with AF.Methods: We studied 1034 Chinese patients...
Source: International Journal of Cardiology - October 24, 2012 Category: Cardiology Authors: Yutao Guo, Ron Pisters, Stavros Apostolakis, Andrew D. Blann, Haijun Wang, Xiaoning Zhao, Yu Zhang, Dexian Zhang, Jingling Ma, Yutang Wang, Gregory Y.H. Lip Tags: Original Articles Source Type: research
Warfarin may reduce risk of ischemic stroke by preventing atrial fibrillation for patients with heart failure and sinus rhythm
As compared with the general population, patients with reduced ejection fraction who are in sinus rhythm are observed with a higher risk for ischemic stroke. This relationship is caused by left ventricular stasis, a systemic hypercoagulable state, and endocardial dysfunction in a situation of impaired left ventricular systolic function . Therefore, the issue whether antithrombotic agents especially aspirin or warfarin could successfully prevent stroke for patients with heart failure and sinus rhythm has been tested in a series of clinical trials. The former two trials (the Warfarin/Aspirin Study in Heart Failure (WASH) tri...
Source: International Journal of Cardiology - July 16, 2012 Category: Cardiology Authors: Gen-Min Lin, Yi-Hwei Li, Lamin .E.S. Jaiteh, Chih-Lu Han Tags: Letters to the Editor Source Type: research
Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors
Abstract: Background: We aimed to assess whether the use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of cardiovascular (CV) events in stable patients with established atherothrombosis or multiple risk factors.Methods: We analysed the 23,728 European patients of the REACH Registry; 20,588 (86.8%) had established atherothrombotic disease and 3140 (13.2%) had multiple risk factors only. Aspirin (ASA) and/or NSAIDs use was determined at enrolment and ischemic events were recorded over two years of follow-up. cMACCE was defined as the composite of CV death, MI or stroke. Bleeding was d...
Source: International Journal of Cardiology - June 30, 2011 Category: Cardiology Authors: Olivier Barthélémy, Tobias Limbourg, Jean Philippe Collet, Farzin Beygui, Johanne Silvain, Anne Bellemain-Appaix, Guillaume Cayla, Thomas Chastre, Iris Baumgartner, Joachim Röther, Uwe Zeymer, Deepak L. Bhatt, Gabriel Steg, Gilles Montalescot, On behal Tags: Original Articles Source Type: research
Apixaban in patients with atrial fibrillation and prior coronary artery disease: Insights from the ARISTOTLE trial
Conclusions: In patients with AF, apixaban more often prevented stroke or systemic embolism and death and caused less bleeding than warfarin, regardless of the presence of prior CAD. Given the common occurrence of AF and CAD and the higher rates of cardiovascular events and death, our results indicate that apixaban may be a better treatment option than warfarin for these high-risk patients.
Source: International Journal of Cardiology - November 4, 2013 Category: Cardiology Authors: Maria Cecilia Bahit, Renato D. Lopes, Daniel M. Wojdyla, Stefan H. Hohnloser, John H. Alexander, Basil S. Lewis, Philip E. Aylward, Freek W.A. Verheugt, Matyas Keltai, Rafael Diaz, Michael Hanna, Christopher B. Granger, Lars Wallentin Tags: Original Articles Source Type: research
Antiplatelet Therapy in Japanese Patients with Atrial Fibrillation without Oral Anticoagulants: Pooled Analysis of Shinken Database, J-RHYTHM Registry and Fushimi AF Registry
Atrial fibrillation (AF) is the most common cardiac arrhythmia and increases the risk of ischemic stroke. Oral anticoagulants (OAC) are effective for stroke prevention in patients with AF, and recent evidences have revealed the efficacy and safety of non-vitamin K antagonist OAC (NOAC) as well as warfarin. Although aspirin was shown to be inferior to warfarin or apixaban in preventing stroke [1,2], it is still prescribed to many AF patients in clinical practice [3–5]. This may be because physicians perceived it to be a safer and more convenient alternative to OAC.
Source: International Journal of Cardiology - April 22, 2015 Category: Cardiology Authors: Hisashi Ogawa, Masaharu Akao, Shinya Suzuki, Takeshi Yamashita, Ken Okumura, Hirotsugu Atarashi, Hiroshi Inoue Tags: Letter to the Editor Source Type: research
Beyond age, the need for useful parameters to identify heart failure patients in sinus rhythm that can benefit from oral anticoagulation
It is still unclear whether oral anticoagulant or aspirin therapy is superior for patients with heart failure (HF) who are in sinus rhythm. The subanalyses of the warfarin vs. aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial, that have been recently published , were aimed to identify subgroups of patients with reduced left ventricular ejection fraction (LVEF≤35%) in sinus rhythm that may benefit from warfarin or aspirin. They showed that patients under 60years have an improved outcome with warfarin over aspirin concerning the composite outcome of ischemic stroke, intracerebral hemorrhage and overall death, wha...
Source: International Journal of Cardiology - January 23, 2014 Category: Cardiology Authors: Enrico Ammirati, Dacia Dalla Libera, Maria Frigerio Tags: Online Letters to the Editor Source Type: research
Reply: Health status, geriatric syndromes and prescription of oral anticoagulant therapy in elderly medical in-patients with atrial fibrillation: A prospective observational study
We agree with the content of the letter from Dr Jolobe OMP and, specifically we concur with his conclusion, where he underlines the fragile evidence for aspirin use in the prevention of atrial fibrillation (AF)-related stroke. According to recent European guidelines [1], our study aimed to assess prevalence of and variables associated with under-prescription of currently recommended anticoagulant therapy for AF patients, including vitamin K antagonists (VKAs) and new direct oral anticoagulants (DOAs), but not those associated with use or under-use of aspirin, which is currently not recommended for prevention of AF-related stroke.
Source: International Journal of Cardiology - April 15, 2015 Category: Cardiology Authors: M. Bo, F. Li Puma, M. Badinella Martini, Y. Falcone, M. Iacovino, E. Grisoglio, M. Bonetto, G. Isaia, G. Ciccone, G.C. Isaia, F. Gaita Tags: Letters to the Editor Source Type: research
Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin
Conclusions: Dual low responsiveness to clopidogrel and aspirin is a strong predictor of cardiac adverse events, especially in patients with diabetes mellitus, which underlines the need for personalized antiplatelet treatment.
Source: International Journal of Cardiology - February 3, 2012 Category: Cardiology Authors: Jolanta M. Siller-Matula, Georg Delle-Karth, Günter Christ, Thomas Neunteufl, Gerald Maurer, Kurt Huber, Alexander Tolios, Christa Drucker, Bernd Jilma Tags: Original Articles Source Type: research
High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting
Abstract: Background: Recent studies have shown that post-clopidogrel high platelet reactivity (HPR), assessed by a point-of-care assay, is associated with a higher risk of adverse events after percutaneous coronary intervention (PCI). We assessed the clinical impact of HPR by the VerifyNow P2Y12 point-of-care assay in 181 patients with ST-segment elevation myocardial infarction (STEMI) who underwent primary PCI with drug-eluting stents (DES) at 3 hospitals.Methods: The primary endpoint of the study was the 12-month major adverse cardiovascular events (MACE), which comprised cardiovascular death, nonfatal MI and ischemic s...
Source: International Journal of Cardiology - June 11, 2012 Category: Cardiology Authors: Han-Young Jin, Tae-Hyun Yang, Doo-Il Kim, Sang-Ryul Chung, Jeong-Sook Seo, Jae-Sik Jang, Dae-Kyeong Kim, Dong-Kie Kim, Ki-Hun Kim, Sang-Hoon Seol, Chang-Wook Nam, Seung-Ho Hur, Woong Kim, Jong-Seon Park, Young-Jo Kim, Dong-Soo Kim Tags: Original Articles Source Type: research
Peripheral artery disease and outcomes after myocardial infarction: An individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT
Abstract: Objectives: To examine the prevalence of peripheral artery disease (PAD) and the relationship between PAD and cardiovascular (CV) outcomes in subjects with left ventricular systolic dysfunction, heart failure or both after acute myocardial infarction (MI).Background: PAD is associated with poorer prognosis in patients with stable and unstable coronary heart disease but whether PAD is associated with worse outcomes following substantial acute MI is unknown.Methods: Univariate and multivariate Cox proportional hazards modelling was used to compare clinical outcomes in an individual-patient meta-analysis of 4 trials...
Source: International Journal of Cardiology - November 29, 2012 Category: Cardiology Authors: Sally C. Inglis, Judith Bebchuk, Sultan A. Al-Suhaim, Jessica Case, Marc A. Pfeffer, Scott D. Solomon, Yingxin (Rachel) Hou, Bertram Pitt, Henry J. Dargie, Ian Ford, John Kjekshus, Faiez Zannad, Kenneth Dickstein, John J.V. McMurray Tags: Original Articles Source Type: research
Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry
Abstract: Background: Patients with atrial fibrillation (AF) are at increased risk of thromboembolic events. The long-term prognostic implications of AF in patients with atherothrombosis are unknown.Methods: We compared 4-year CV outcomes in patients with and without a history of AF recorded at their baseline visit in the REACH Registry, an international, prospective cohort of patients with established atherosclerotic arterial disease (CAD, CVD, PAD) or at least 3 risk factors (RFO).Results: AF status and 4year follow-up data were available on 44,518 patients. The prevalence of AF at baseline was 10.3% (n=4582). Overall, p...
Source: International Journal of Cardiology - December 9, 2013 Category: Cardiology Authors: Christian T. Ruff, Deepak L. Bhatt, Ph. Gabriel Steg, Bernard J. Gersh, Mark J. Alberts, Elaine B. Hoffman, E. Magnus Ohman, Kim A. Eagle, Gregory Y.H. Lip, Shinya Goto, On Behalf of the REACH Registry Investigators Tags: Original Articles Source Type: research
Dual antiplatelet therapy versus warfarin anticoagulation in patients undergoing catheter ablation of atrial fibrillation
Radio frequency catheter ablation (RFCA) has become a standard treatment for patients with atrial fibrillation (AF) . Anticoagulation in patients undergoing AF ablation is crucial to minimize the risk of thromboembolic complications. Although warfarin is effective in reducing stroke, its chronic use has many disadvantages including frequent international normalized ratio (INR)/prothrombin, attention to numerous dietary and medication interactions, and risk of serious bleeding including intracranial hemorrhage . Novel oral anticoagulants provide a reasonable alternative; however, they cannot yet be reversed, are expensive, ...
Source: International Journal of Cardiology - March 28, 2014 Category: Cardiology Authors: Zhiyu Ling, Fengpeng Jia, Yanping Xu, Li Su, Zengzhang Liu, Huaan Du, Xiaoyu Yang, Xianbin Lan, Peilin Xiao, Weijie Chen, Jinqi Fan, Suxin Luo, Yuehui Yin, Saman Nazarian Tags: Letters to the Editor Source Type: research
Acute Myocardial Infarction and Acute Stroke: Between a Rock and a Hard Place
A 53year-old woman developed severe chest pain, breathlessness and palpitations whilst being told some very devastating news. As the symptoms persisted for more than 15minutes, electrocardiography was undertaken in the community confirming an anterolateral STEMI. Following the electrocardiographic findings the patient was loaded orally in the community with aspirin 300mg and clopidogrel 600mg and was urgently transferred via the community activation primary PCI route to our institution for emergency coronary angiography.
Source: International Journal of Cardiology - October 22, 2014 Category: Cardiology Authors: Vassilios Vassiliou, Bushra Rana, Martin Goddard, Denise Braganza Tags: Letter to the editor Source Type: research
Risk stratification for secondary prevention with ticagrelor and aspirin: A closer look to patient subsets from the PEGASUS-TIMI 54 trial
In the PEGASUS trial, 21,162 patients with a history of myocardial infarction within 1 to 3years earlier were randomized to ticagrelor 90mg twice daily, ticagrelor 60mg twice daily or placebo on a background of low-dose aspirin, and were followed for a median of 33months [1]. Both doses of ticagrelor significantly reduced the primary efficacy endpoint (a composite of cardiovascular death, myocardial infarction, or stroke) but also increased the primary safety endpoint (TIMI major bleeding), compared with placebo [1].
Source: International Journal of Cardiology - August 5, 2015 Category: Cardiology Authors: Davide Capodanno, Piera Capranzano, Sergio Buccheri, Corrado Tamburino Tags: Letter to the Editor Source Type: research
